APA

Kawaguchi T., Kodama T., Hikita H., Makino Y., Saito Y., Tanaka S., Shimizu S., Sakamori R., Miyagi T., Wada H., Nagano H., Hiramatsu N., Tatsumi T. & Takehara T. (2015). Synthetic lethal interaction of combined CD26 and Bcl-xL inhibition is a powerful anticancer therapy against hepatocellular carcinoma. : Hepatology research : the official journal of the Japan Society of Hepatology.

Chicago

Kawaguchi Tsukasa, Kodama Takahiro, Hikita Hayato, Makino Yuki, Saito Yoshinobu, Tanaka Satoshi, Shimizu Satoshi, Sakamori Ryotaro, Miyagi Takuya, Wada Hiroshi, Nagano Hiroaki, Hiramatsu Naoki, Tatsumi Tomohide and Takehara Tetsuo. 2015. Synthetic lethal interaction of combined CD26 and Bcl-xL inhibition is a powerful anticancer therapy against hepatocellular carcinoma. : Hepatology research : the official journal of the Japan Society of Hepatology.

Harvard

Kawaguchi T., Kodama T., Hikita H., Makino Y., Saito Y., Tanaka S., Shimizu S., Sakamori R., Miyagi T., Wada H., Nagano H., Hiramatsu N., Tatsumi T. and Takehara T. (2015). Synthetic lethal interaction of combined CD26 and Bcl-xL inhibition is a powerful anticancer therapy against hepatocellular carcinoma. : Hepatology research : the official journal of the Japan Society of Hepatology.

MLA

Kawaguchi Tsukasa, Kodama Takahiro, Hikita Hayato, Makino Yuki, Saito Yoshinobu, Tanaka Satoshi, Shimizu Satoshi, Sakamori Ryotaro, Miyagi Takuya, Wada Hiroshi, Nagano Hiroaki, Hiramatsu Naoki, Tatsumi Tomohide and Takehara Tetsuo. Synthetic lethal interaction of combined CD26 and Bcl-xL inhibition is a powerful anticancer therapy against hepatocellular carcinoma. : Hepatology research : the official journal of the Japan Society of Hepatology. 2015.